Copy to clipboard 
Evonik acquired the Endexo® surface modification business of Interface Biologics.
Endexo is a proprietary additive with macromolecules that enhance the biocompatibility of medical devices that come into contact with blood, tissue or other biological fluids. The low molecular weight fluoro-oligomeric additives migrate to the top few nanometers of a device’s surface without any changes required in the manufacturing process.
In the presence of blood, Endexo-modified surfaces can suppress procoagulant protein conformation, reduce platelet adhesion and inhibit platelet activation. In the presence of bacteria-mediated fluids, modified surfaces can effectively reduce bacterial adhesion and encrustation. The Endexo platform technology can be applied to a variety of base polymers and manufacturing techniques and become an integral part of the base material without compromising device functionality.
A number of medical device companies have licensed the use of Endexo technology in cardiovascular and other applications. Some products are already commercially available, while others are part of clinical trials. Evonik plans to further expand the geographic and application footprint of Endexo.
Sources: Evonik and Interface Biologics
